ESC 365 - The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial

ESC Professional Premium Access

The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial

Session: Focus on the pulmonary vascular bed

Topic: Pharmacotherapy

Speaker: Doctor P. Clift (Birmingham, GB)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Paul Clift

Queen Elizabeth Hospital Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

2 presentations

1 follower

4 more presentations in this session

Ventricular-arterial coupling predicts outcomes in adults with a systemic right ventricle

Speaker: Doctor G. Pasqualin (Milan, IT)

Inactivation of catalytic and non-catalytic PI3 kinase gamma functions enhances hypoxia-induced pulmonary hypertension in mice

Speaker: Mrs L. Gnatzy-Feik (Cologne, DE)

Investigating monotherapy and combination therapy trends in newly diagnosed patients with pulmonary arterial hypertension among EU3 & UK physicians over the COVID-19 pandemic.

Speaker: Mr D. Chandler (London, GB)

Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study

Speaker: Doctor R. Bravo-Marques (Marbella, ES)

Access the full session

Focus on the pulmonary vascular bed

Speakers: Doctor P. Clift, Doctor G. Pasqualin, Mrs L. Gnatzy-Feik, Mr D. Chandler, Doctor R. Bravo-Marques

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources